Skip to main content

Table 4 Changes in individual REVEAL components at ≥6-month time point

From: Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study

Component

n

Baseline score, mean (SD)

≥6-month score, mean (SD)

Mean change (95% CI)

p-value

WHO FC (as continuous)

72

2.1 (0.7)

2.8 (0.7)

−0.7 (−0.8, −0.5)

< 0.0001

SBP, mm Hg

72

120.4 (17.1)

117.9 (15.6)

−2.5 (−6.4, 1.4)

0.0476

Heart rate, beats/min

73

77.8 (12.1)

77.0 (13.8)

−0.8 (−4.3, 2.8)

0.5057

6-min walk test, m

46

364.5 (133.3)

406.3 (112.3)

41.8 (14.5, 69.2)

0.0003

BNP, pg/mL

16

310.1 (350.2)

152.5 (164.8)

−157.6 (− 336.3, −21.1)

0.0229

NT-proBNP, pg/mL

37

1121.1 (1497.4)

590.6 (630.4)

−530.0 (− 972.0, −88.9)

0.0014

DLCO, % predicted

23

52.7 (18.0)

50.8 (19.2)

−1.9 (− 1.6, 5.5)

0.2753

mRAP, mm Hg

12

7.9 (4.0)

7.7 (2.6)

−0.3 (−1.6, 2.1)

0.4939

PVR, WU

13

11.5 (4.6)

8.1 (3.4)

−3.4 (−6.5, −0.2)

0.0033

  1. Significant p-values are marked in bold
  2. BNP brain natriuretic peptide, CI confidence interval, DLCO diffusing capacity of the lungs for carbon monoxide, FC functional class, mRAP mean right atrial pressure, NT-proBNP N-terminal pro-BNP, PAH pulmonary arterial hypertension, PVR pulmonary vascular resistance, Q1 25th percentile, Q3 75th percentile, SD standard deviation, SBP systolic blood pressure, WHO World Health Organization, WU Wood units